12:00 AM
Jun 02, 2008
 |  BioCentury  |  Strategy

RNAi(ndependence), Part II

RNAi(ndependence), Part II

By Stephen Hansen Staff Writer

Alnylam Pharmaceuticals Inc. landed an RNAi deal with Roche last year that provided an influx of cash without requiring it to sell the farm through an exclusive deal. Last week, the biotech made good on its plan to sign similar broad, non-exclusive licensing deals for its RNAi platform through a pact with Takeda Pharmaceutical Co. Ltd. The deal provides not only non-dilutive cash, but an opportunity to take part in co-development and potentially build a sales force.

While the Roche deal provided more money up front, VP of Business Development Jason Rhodes said the Takeda alliance is by no means inferior.

Alnylam granted Roche a non-exclusive license to RNAi technology in four disease areas for $331 million up front, which included a $42.5 million equity investment and...

Read the full 666 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >